Does Medicare Cover esketamine (Spravato) and Ketamine Therapy?
Medicare Part B covers esketamine (Spravato) for adults with treatment-resistant depression when administered in a certified healthcare setting, but it generally does not cover off-label ketamine therapy.
Lumin Health offers ketamine therapy and Spravato treatment at four locations across Greater Boston.
Coverage for esketamine typically applies when a patient has not responded to at least two adequate trials of oral antidepressants. Off-label ketamine treatment — delivered via intramuscular (IM) injection at Lumin Health — is generally not covered by Medicare, though many patients pursue it as a self-pay option.
If you are on Medicare and living with depression that has not responded to standard medications, the distinction between what is covered and what is not can feel like one more barrier in a long line of them. This article is designed to help you understand exactly how Medicare handles these treatments, what the authorization process looks like, and where Lumin Health fits into the picture — so the logistics become less of a burden and more of a clear path forward.
How Medicare Part B Covers esketamine (Spravato)
esketamine (Spravato) is FDA-approved for two specific populations: adults with treatment-resistant depression — defined as depression that has not responded to at least two adequate courses of antidepressant treatment — and adults with major depressive disorder accompanied by active suicidal ideation or behavior. Because it is administered in a certified healthcare setting under direct clinical supervision, it falls under Medicare Part B as an outpatient medical service rather than a pharmacy benefit.
Ready to explore ketamine therapy?
Lumin Health offers expert-led ketamine and Spravato treatment in Massachusetts and the greater Washington DC/Maryland area. Start with a free consultation to see if it could help you.
Available in Massachusetts and the greater Washington DC/Maryland area.
This is an important distinction. Unlike medications you pick up at a pharmacy (which would fall under Part D), esketamine (Spravato) is billed as a medical procedure. For most Medicare beneficiaries, this means:
- Part B covers the medication itself when administered in a REMS-certified setting.
- The mandatory two-hour post-dose observation period is typically included in the covered service.
- You are responsible for the standard Part B coinsurance — usually 20% of the Medicare-approved amount after your annual deductible has been met.
- If you have a Medicare Supplement (Medigap) plan, it may cover some or all of your remaining coinsurance.
The clinical requirement is clear: to qualify for Medicare coverage, your treating provider must document that you meet the FDA-approved indication. For the treatment-resistant depression pathway, this means demonstrating inadequate response to at least two prior antidepressant trials. For the major depressive disorder with suicidal ideation pathway (sometimes called MDDSSI), you do not need to have tried and not responded to prior antidepressants — active suicidal thoughts with a qualifying severity score are sufficient.
The Authorization Process: What to Expect Step by Step
One of the most common concerns we hear from patients is not whether the treatment itself might help, but whether they can actually get it approved. Insurance authorization — even with Medicare — involves documentation, clinical justification, and sometimes patience. Here is what the process typically looks like at Lumin Health.
Step 1: Clinical Evaluation. Every patient who comes to Lumin Health begins with a comprehensive psychiatric evaluation. This is not a screening call or a questionnaire — it is a face-to-face meeting with a physician or nurse practitioner specifically trained in ketamine and esketamine treatment. During this evaluation, your provider reviews your full medication history, prior treatment responses, current symptom severity, and medical history to determine whether esketamine (Spravato) is clinically appropriate.
Step 2: Insurance Verification and Prior Authorization. Our team submits a prior authorization request to Medicare on your behalf. This documentation includes your diagnosis, the treatments you have already tried, your current depression severity (measured using validated scales), and the clinical rationale for esketamine. Each insurance entity adds its own nuance to how treatment-resistant depression is defined, which is why having an organization experienced in navigating these requirements matters significantly.
Step 3: Pharmacy Logistics. Based on your specific Medicare coverage, esketamine (Spravato) may be delivered to the practice through one of two pathways. Some plans require that a specialty pharmacy ships the medication directly to the practice specifically for you. Other plans allow the practice to stock the medication and bill Medicare directly. Our administrative team manages this process so you do not have to navigate specialty pharmacy logistics on your own.
Step 4: Treatment Begins. Once authorization is secured and medication logistics are in place, treatment can begin. The standard schedule involves twice-weekly sessions during the first four weeks (the induction phase), transitioning to weekly or biweekly sessions during the maintenance phase. You self-administer the nasal spray under clinical supervision, remain for a two-hour observation period, and arrange transportation home — you cannot drive for the remainder of the day after treatment.
Does Medicare Pay for Ketamine Therapy? Understanding Off-Label Coverage
This is where the picture becomes less straightforward. The question of whether Medicare covers ketamine for depression requires understanding the difference between FDA-approved and off-label treatments.
Ketamine — the racemic mixture containing both S-ketamine and R-ketamine molecules — is FDA-approved only as an anesthetic. When used for depression, anxiety, or other psychiatric conditions, it is an off-label application. Off-label prescribing is legal, common across medicine, and supported by a growing body of clinical evidence. However, Medicare generally does not cover off-label ketamine for psychiatric indications.
At Lumin Health, we provide intramuscular (IM) ketamine injections because they offer an efficient, comfortable experience compared to slower IV infusions. These sessions are priced at $500 per session. We provide a Superbill — an itemized receipt — that patients with out-of-network PPO benefits can submit to their supplemental insurance for potential partial reimbursement. But for patients whose only coverage is traditional Medicare, IM ketamine treatment is typically a fully out-of-pocket expense.
This does not diminish the clinical value of ketamine therapy. A systematic review and meta-analysis comparing racemic ketamine and esketamine found that both demonstrate meaningful antidepressant effects, with each offering distinct advantages depending on clinical context. For patients whose depression has not responded to standard medications, ketamine for depression represents an evidence-based option — the coverage landscape simply has not caught up to the science.
Why the Coverage Distinction Matters Clinically
When we talk about depression that has resisted multiple treatments, we are not talking about a lack of willpower or effort. Treatment-resistant depression reflects rigid neurological patterns — thought loops, behavioral withdrawal, and emotional blunting that become written in the brain's circuitry over time. The Default Mode Network, which governs self-referential thinking, can become overactive and inflexible, trapping a person in cycles of rumination and hopelessness. Your brain isn't broken — it may just be stuck.
Both ketamine and esketamine work through the glutamate system — fundamentally different from the serotonin, norepinephrine, and dopamine pathways that traditional antidepressants target. This glutamatergic action helps the brain form new connections, promoting neuroplasticity so patients can break out of entrenched patterns. Research continues to clarify the scope and durability of these effects, with long-term safety data informing how clinicians structure ongoing treatment.
The coverage distinction between esketamine (Spravato) and off-label ketamine treatment is purely regulatory, not clinical. Both act on overlapping receptor systems. Both can create what our clinicians describe as a biologically receptive window for change — a period when the brain is more capable of learning new patterns, whether through a patient's own self-guided practice, behavioral support, or other work the patient pursues independently.
Medicare Advantage Plans: A Different Landscape
If you are enrolled in a Medicare Advantage plan (Part C) rather than Original Medicare, your coverage for esketamine (Spravato) may look different. Medicare Advantage plans are administered by private insurers and must cover everything Original Medicare covers, but they can impose their own prior authorization requirements, preferred provider networks, and cost-sharing structures.
Some Medicare Advantage plans have been more restrictive with coverage than Original Medicare. Others have been more accommodating. The variability is significant enough that we strongly recommend verifying your specific coverage before beginning treatment. You can do this by contacting your plan directly or by using the eligibility tools on our insurance page.
At Lumin Health, we accept Medicare alongside a range of commercial insurers including Aetna, Anthem, Blue Cross Blue Shield, Cigna, Evernorth, Harvard Pilgrim, Optum, Point32Health, and United Healthcare. Our administrative team is experienced in working with Medicare's authorization requirements and can help clarify what your specific plan covers before your first appointment.
What Medicare Does Not Cover — and What to Do About It
Beyond off-label ketamine, there are a few other gaps in Medicare's mental health benefits that patients should be aware of:
- Medicare does not cover the cost of transportation to and from treatment sessions, even though you are required to have a ride home after each esketamine dose.
- If your Medicare plan has a deductible, you will need to meet it before Part B coverage kicks in at 80%.
- Some Medicare Supplement plans cover the 20% coinsurance; others do not — check your specific Medigap policy.
- Medicare Part D does not apply to esketamine (Spravato) because it is administered in a clinical setting, not dispensed at a retail pharmacy.
For patients who find that cost remains a barrier even with Medicare coverage, the manufacturer's savings programs may offer additional assistance. These programs are typically designed for commercially insured patients, but it is worth inquiring about any available support through the Spravato withMe program, particularly if you have supplemental coverage.
Navigating the System When You Are Already Exhausted
There is a particular cruelty in asking someone whose depression has resisted years of treatment to then navigate a complex insurance authorization process. The very symptoms that bring you to this point — low energy, difficulty concentrating, a sense that nothing will work — are the same symptoms that make paperwork and phone calls feel impossible.
This is part of why the administrative infrastructure at a practice matters as much as the clinical expertise. As an organization rooted in Massachusetts and expanding to other states, our team at Lumin Health handles the prior authorization, pharmacy coordination, and insurance communication so that your primary task is showing up. We verify your mental health benefits before your first session, explain what you will owe in plain terms, and flag any coverage issues before they become surprises.
"Part of the model at Lumin Health is that everybody who has an intake meets with a psychiatrist or a psychiatric nurse practitioner. We are not only expert over the conditions that bring people to us, but expert over the treatments we provide."
— Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health
If you are on Medicare and wondering whether ketamine therapy or esketamine (Spravato) could be right for you, the first step is not a commitment — it is a conversation. Our team can review your coverage, explain the authorization timeline, and help you understand what treatment would look like before any clinical decisions are made.
Frequently Asked Questions
Does Medicare cover esketamine (Spravato) for depression?
Yes. Medicare Part B covers esketamine (Spravato) when administered in a REMS-certified healthcare setting for adults with treatment-resistant depression or major depressive disorder with suicidal ideation. You are typically responsible for the standard 20% Part B coinsurance after meeting your annual deductible.
Does Medicare pay for intramuscular (IM) ketamine therapy?
Generally, no. Off-label ketamine treatment for psychiatric conditions is not covered by Medicare. At Lumin Health, IM ketamine sessions are $500 per session, and we provide a Superbill for patients who wish to seek reimbursement through their out-of-network supplemental insurance benefits.
How long does Medicare prior authorization for esketamine (Spravato) take?
Authorization timelines vary, but most Medicare prior authorizations for esketamine (Spravato) are processed within one to two weeks. Our team submits all required documentation and follows up directly with Medicare to minimize delays.
Can I get esketamine (Spravato) if I have Medicare Advantage?
Medicare Advantage plans must cover what Original Medicare covers, but they may impose additional prior authorization requirements or cost-sharing structures. We recommend verifying your specific plan's coverage by visiting lumin.health/insurance-we-accept or contacting your plan directly.
What if I cannot afford the coinsurance for esketamine (Spravato) under Medicare?
If you have a Medigap plan, it may cover some or all of the 20% coinsurance. Janssen, themanufacturer of esketamine (Spravato), also offers patient support programs that may be applicable depending on your supplemental coverage. Our administrative team can help you explore available options by verifying your benefits at lumin.health/insurance-we-accept.
If you are exploring whether esketamine (Spravato) or ketamine for depression may be appropriate for your situation, we would be grateful to walk with you through the process — from coverage verification to your first session. Explore whether this may be a fit and check your insurance eligibility with our team today.
Find out if ketamine therapy is covered by your plan.
Lumin Health accepts most major insurance providers for Spravato treatment in Massachusetts and the greater Washington DC/Maryland area. Use our free tool to check your coverage instantly — no forms, no phone calls.
Available in Massachusetts and the greater Washington DC/Maryland area.
